U.S. Markets close in 2 hrs 38 mins

Delcath Systems, Inc. (DCTH)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
12.72+0.14 (+1.07%)
As of 1:22PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close12.58
Open12.60
Bid12.70 x 1100
Ask12.73 x 900
Day's Range12.31 - 12.72
52 Week Range5.15 - 95.90
Volume20,027
Avg. Volume61,649
Market Cap49.514M
Beta (5Y Monthly)0.41
PE Ratio (TTM)N/A
EPS (TTM)-496.64
Earnings DateAug 13, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.50
  • GlobeNewswire

    Delcath Schedules Conference Call to Report 2020 Second Quarter Financial Results

    NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced that it will host a conference call on August 13, 2020 at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2020. Conference Call InformationTo participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the Delcath Second Quarter Conference Call when reaching an operator.Date: August 13, 2020 Time: 4:30 PM Eastern Time Toll Free: (833) 937-1050 International: (845) 403-8302The call will also be available over the Internet and accessible at: https://www.webcaster4.com/Webcast/Page/2475/36568.About Delcath Systems, Inc.Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) – is designed to administer high-dose chemotherapy to the liver while minimizing systemic exposure and associated side effects. In addition to the Phase 3 FOCUS Trial, we have initiated a global Phase 3 clinical trial for intrahepatic cholangiocarcinoma (ICC) called The ALIGN Trial. We currently are also evaluating other forms of metastatic liver cancers. Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.Contact:Hayden IR James Carbonara (646)-755-7412 james@haydenir.comBrett Maas (646) 536-7331 brett@haydenir.com

  • ACCESSWIRE

    LD Micro - Announces Preliminary List of Presenters for the LD-500

    LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

  • GlobeNewswire

    Delcath to Present at Canaccord Genuity 40th Annual Growth Conference

    NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced that John Purpura, interim Chief Executive Officer, will be presenting virtually on Wednesday, August 12, 2020 at 9 a.m. ET in Track 5 at the Canaccord Genuity 40th Annual Growth Conference. A webcast of the presentation will be available at the following link: http://wsw.com/webcast/canaccord42/dcth/   The Company will also be participating in one-on-one investor meetings. To schedule a meeting, please contact your Canaccord representative or email James@HaydenIR.comAbout Delcath Systems, Inc.Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) – is designed to administer high-dose chemotherapy to the liver while minimizing systemic exposure and associated side effects. In addition to the Phase 3 FOCUS Trial, we have initiated a global Phase 3 clinical trial for intrahepatic cholangiocarcinoma (ICC) called The ALIGN Trial. We currently are also evaluating other forms of metastatic liver cancers.  Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath  CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.Contact:Hayden IR James Carbonara (646)-755-7412 james@haydenir.com Brett Maas (646) 536-7331 brett@haydenir.com